Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients

BACKGROUND: This study aimed to evaluate possible treatment strategies for patients with de novo T790M mutation‐positive (T790M+) non‐small‐cell lung cancer (NSCLC). METHODS: Patients diagnosed with de novo T790M+ NSCLC and treated with epidermal growth factor receptor tyrosine kinase inhibitors (EG...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, John Wen‐Cheng, Huang, Chen‐Yang, Fang, Yueh‐Fu, Chang, Ching‐Fu, Yang, Cheng‐Ta, Kuo, Chih‐Hsi Scott, Hsu, Ping‐Chih, Wu, Chiao‐En
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250841/
https://www.ncbi.nlm.nih.gov/pubmed/35633141
http://dx.doi.org/10.1111/1759-7714.14272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250841/
https://www.ncbi.nlm.nih.gov/pubmed/35633141
http://dx.doi.org/10.1111/1759-7714.14272

Ejemplares similares